JP Morgan resumed coverage on NovoCure with a new price target
$NVCR
Medical/Dental Instruments
Health Care
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $18.00 → $30.00 | In-line → Outperform | Evercore ISI |
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2023 | $15.00 | Neutral | JP Morgan |
| 8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright |
| 8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler |
| 8/4/2023 | $51.00 | Outperform | SVB Securities |
| 7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
| 6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
8-K - NovoCure Ltd (0001645113) (Filer)
8-K - NovoCure Ltd (0001645113) (Filer)
8-K - NovoCure Ltd (0001645113) (Filer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)